WG
DNLI icon

Winton Group’s Denali Therapeutics DNLI Stock Holding History

Winton Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363K Sell
14,100
-57,079
-80% -$1.17M 0.01% 815
2026
Q1 		$1.37M Buy
71,179
+58,479
+460% +$1.16M 0.05% 422
2025
Q4 		$210K Buy
+12,700
New +$214K 0.01% 822
2022
Q1 		– Sell
-6,272
Closed -$280K – 1006
2021
Q4 		$280K Buy
+6,272
New +$297K 0.02% 853
2020
Q1 		– Sell
-45,452
Closed -$792K – 1429
2019
Q4 		$792K Buy
+45,452
New +$757K 0.01% 1119

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's DNLI Position: Q2 2026 in Review

Winton Group reduced its Denali Therapeutics (DNLI) stake by 80% in Q2 2026, selling an estimated $1.17M and leaving 14,100 shares worth $363K. The position accounts for 0.01% of the portfolio, ranked #815.

Winton Group first reported a position in DNLI in Q4 2019 and has held it in 5 quarters since. The position peaked at $1.37M in Q1 2026. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Winton Group held 14,100 shares of Denali Therapeutics worth $363K as of Q2 2026.
  • Winton Group sold 57,079 Denali Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Denali Therapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #815 holding.
  • Winton Group first reported a position in Denali Therapeutics in Q4 2019 and has held it in 5 quarters since.
  • Winton Group's Denali Therapeutics position peaked at $1.37M in Q1 2026.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.